Dimerix (ASX:DXB) ROCE % : -150.50% (As of Dec. 2023)

View and export this data going back to 1993. Start your Free Trial

What is Dimerix ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Dimerix's annualized ROCE % for the quarter that ended in Dec. 2023 was -150.50%.

Dimerix ROCE % Historical Data

The historical data trend for Dimerix's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dimerix ROCE % Chart

Dimerix Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

ROCE %

Get a 7-Day Free Trial

-78.44

-115.67

-236.84

-212.72

-222.94

Dimerix Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial															-132.96	-125.78	-199.56	-483.65	-150.50

Dimerix ROCE % Calculation

Dimerix's annualized ROCE % for the fiscal year that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	-22.823	/	( ( (16.497 - 2.024)	+	(17.758 - 11.756) )	/ 2 )
	=	-22.823	/	( (14.473	+	6.002)	/ 2 )
	=	-22.823	/	10.2375
	=	-222.94 %

Dimerix's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-13.528	/	( ( (17.758 - 11.756)	+	(15.089 - 3.113) )	/ 2 )
	=	-13.528	/	( ( 6.002	+	11.976 )	/ 2 )
	=	-13.528	/	8.989
	=	-150.50 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Dimerix (ASX:DXB) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Dimerix ROCE % Related Terms

Thank you for viewing the detailed overview of Dimerix's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Dimerix (ASX:DXB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dimerix Ltd (ASX:DXB) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

425 Smith Street, Fitzroy, VIC, AUS, 3065

Website

https://www.dimerix.com

Dimerix Ltd is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs. The company is developing five product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney disease; DMX-200 for COVID-19 pneumonia patients in ICU; DMX-200 for respiratory complications in Covid-19 patients; and DMX-700 for COPD; as well as the proprietary ReceptorHIT assay technology.

Dimerix (ASX:DXB) Headlines

No Headlines